ATE325607T1 - Aptoptoseinhibitoren - Google Patents

Aptoptoseinhibitoren

Info

Publication number
ATE325607T1
ATE325607T1 AT98954719T AT98954719T ATE325607T1 AT E325607 T1 ATE325607 T1 AT E325607T1 AT 98954719 T AT98954719 T AT 98954719T AT 98954719 T AT98954719 T AT 98954719T AT E325607 T1 ATE325607 T1 AT E325607T1
Authority
AT
Austria
Prior art keywords
substituted
group
compound
formula
ring
Prior art date
Application number
AT98954719T
Other languages
English (en)
Inventor
Junji Matsui
Naoki Tarui
Yu Momose
Ken-Ichi Naruo
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE325607T1 publication Critical patent/ATE325607T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98954719T 1997-11-19 1998-11-18 Aptoptoseinhibitoren ATE325607T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP31792697 1997-11-19

Publications (1)

Publication Number Publication Date
ATE325607T1 true ATE325607T1 (de) 2006-06-15

Family

ID=18093586

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98954719T ATE325607T1 (de) 1997-11-19 1998-11-18 Aptoptoseinhibitoren

Country Status (8)

Country Link
US (3) US6087384A (de)
EP (1) EP1047423B1 (de)
AT (1) ATE325607T1 (de)
AU (1) AU1172999A (de)
CA (1) CA2311125C (de)
DE (1) DE69834508T2 (de)
ES (1) ES2259459T3 (de)
WO (1) WO1999025346A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1006794B1 (de) * 1997-03-12 2007-11-28 Robert W. Esmond Verfahren zur behandlung oder prävention der alzheimerischen krankheit
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6613785B2 (en) 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
AP2001002036A0 (en) * 1998-07-21 2001-03-31 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing apoptosis.
US20020099082A1 (en) * 1998-07-21 2002-07-25 Smithkline Beecham P.L.C. Use of glucose uptake enhancer for reducing apoptosis
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
AU3073600A (en) * 1999-01-19 2000-08-07 Sankyo Company Limited Inhibitor for nerve cell death due to glutamic acid cytotoxicity
US20020006942A1 (en) * 2000-02-24 2002-01-17 Davis Roger A. Methods of treating liver disorders and disorders associated with liver function
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
FR2841141A1 (fr) * 2002-06-24 2003-12-26 Exonhit Therapeutics Sa Nouvelles approches therapeutiques de la sclerose lateral amyotrophique
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
GB0324574D0 (en) * 2003-10-21 2003-11-26 Glaxo Group Ltd Novel compositions
WO2005065663A1 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone and metformin formulations
EP1732513A2 (de) * 2003-12-31 2006-12-20 Alpharma, Inc. Formulierungen von rosiglitazon
GB2410948A (en) * 2004-02-13 2005-08-17 Sandoz Ag Novel phosphoric acid salt of rosiglitazone
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
WO2009043593A1 (en) * 2007-10-05 2009-04-09 Merz Pharma Gmbh & Co. Kgaa Combination therapy using memantine and glitazones
JP5382879B2 (ja) 2007-12-13 2014-01-08 国立大学法人九州大学 薬物含有ナノ粒子
US20100049284A1 (en) * 2008-05-15 2010-02-25 The Catholic University Of America Use of heat to treat biological systems exposed to damaging radiation
CA2735578C (en) * 2008-08-12 2018-10-23 Zinfandel Pharmaceuticals, Inc. Method of identifying risk factors for alzheimer's disease comprising tomm40 gene variants
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
EA201391017A1 (ru) 2011-01-10 2014-04-30 Зинфандел Фармасьютикалз, Инк. Способы и готовые лекарственные формы для лечения болезни альцгеймера
GB201805554D0 (en) * 2018-04-04 2018-05-16 Wren Therapeutics Therapy for protein misfolding disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
SE9302332D0 (sv) * 1993-07-06 1993-07-06 Ab Astra New compounds
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
JP3029768B2 (ja) * 1994-04-18 2000-04-04 三共株式会社 悪液質改善剤
IT1280417B1 (it) * 1995-04-14 1998-01-20 Alfa Wassermann Spa Composti a struttura 3,4 diidro-2-iodometil-2,5,7,8-tetrametil-2h-1 benzopiranica.
IL118778A (en) * 1995-07-03 1999-07-14 Sankyo Co Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
JPH09323930A (ja) * 1996-04-04 1997-12-16 Takeda Chem Ind Ltd 悪液質の予防・治療剤
JPH09291031A (ja) * 1996-04-24 1997-11-11 Yamanouchi Pharmaceut Co Ltd 脂質代謝改善剤
US6242196B1 (en) * 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
GEP20033045B (en) * 1998-09-17 2003-08-25 Bristol Myers Squibb Co Method for Treating Diabetes
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
CA2311125C (en) 2011-01-18
AU1172999A (en) 1999-06-07
DE69834508D1 (de) 2006-06-14
US6399639B1 (en) 2002-06-04
US20020086883A1 (en) 2002-07-04
EP1047423B1 (de) 2006-05-10
WO1999025346A1 (en) 1999-05-27
CA2311125A1 (en) 1999-05-27
DE69834508T2 (de) 2006-11-23
ES2259459T3 (es) 2006-10-01
US6555565B2 (en) 2003-04-29
US6087384A (en) 2000-07-11
EP1047423A1 (de) 2000-11-02

Similar Documents

Publication Publication Date Title
ATE325607T1 (de) Aptoptoseinhibitoren
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
CA2116387A1 (en) Oxazolidinedione derivatives, their production and use
TW370450B (en) Substituted 1H-3-aryl-pyrrolidine-2,4-dione derivatives
MXPA04004037A (es) Compuestos novedosos de 1, 2, 4-de triazol.
DE69133299D1 (de) Aminosulfonylcarbamate
TR200000946T2 (tr) İkameli füzyonlu heterosiklik bileşimi
WO1999009965A3 (en) Anti-inflammatory agent
DK249089A (da) Benzamid-forbindelser, der er nyttige som protease-inhibitorer
ES2054826T3 (es) Peptidos con actividad inhibidora de colagenasa.
UA41290C2 (uk) Гетероариламіни, фармацевтична композиція, спосіб інгібування холінестерази у ссавців, спосіб покращення пам'яті
ATE234298T1 (de) Zyklische etherverbindungen als natriumkanal- modulatoren
EA200100310A1 (ru) Кислородсодержащие гетероциклические соединения
ES2044013T3 (es) Compuesto mesomorfico, una composicion de cristal liquido que contiene el compuesto y un dispositivo de cristal liquido que utiliza la composicion.
DK0946788T3 (da) Fremgangsmåde til beskyttelse af metaloverflader mod korrosion i flydende eller gasformige medier
MY100115A (en) Nitrogen containing heterocyclic compounds, and their production and use.
TR200200360T2 (tr) Antibakteriyel aktif maddeler.
ES467697A1 (es) Procedimiento para la obtencion de protectores contra la in-flamacion a base de derivados del acido fosfonocarboxilico
DE69726716T2 (de) Antikachektische zusammensetzung
ATE247660T1 (de) Furopyridinderivate und ihre therapeutische verwendung
BG105123A (en) Tetrahydroquinaline derivatives as glycine antagonists
SE8203877L (sv) Aminosulfonylbensoesyraderivat
BG101156A (bg) Използване на бензалдехиди за маркиране на въглеводороди
HUP0301258A2 (hu) Aminoizokinolincsoportot tartalmazó trombin inhibitorok és alkalmazásuk gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1047423

Country of ref document: EP